UPS (NYSE:UPS), a global leader in logistics, today announced that it is working with QIAGEN, a leading global provider of molecular diagnostics and sample preparation technologies, to deliver nucleic acid extraction kits critical to COVID-19 testing, as well as its novel QIAstat-Dx Coronavirus testing cartridges to destinations around the world. With governments and public authorities classifying UPS as an essential service provider, the company is combining the flexibility of its global network with QIAGEN’s increased production capacity for COVID-19 testing kits produced at their facility in Hilden, Germany to help healthcare workers curb the spread of the disease.

　　“Customers and governments around the world are turning to the reliability of UPS’s smart global logistics network to help fight this pandemic,” said Lou Rivieccio, president, UPS Europe. “Business continuity has never been more important for our customers and that is what we continue to deliver whether it be for delivery or storage of medicines, testing kits or medical supplies. And when it comes to ensuring that increased production volumes of testing kits reach vital destinations around the world such as hospitals and labs, our teams are here to help customers navigate complexity and focus on fighting this pandemic. Agility, flexibility and fast response in the supply chain arena are helping to combat this outbreak as it shifts from Asia to Europe and North America.”